Aadi bioscience appoints mohammad hirmand, m.d. to board of directors

Los angeles , march 27, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mtor pathway genes, today announced the appointment of mohammad hirmand, m.d. to its board of directors.
AADI Ratings Summary
AADI Quant Ranking